Role of H2 receptor blocker famotidine over the clinical recovery of COVID-19 patients: A randomized controlled trial

Table 5 Analysis of the hospital stay, intensive care unit stay, time to symptomatic recovery, and time to negative polymerase chain reaction among the recovered patients against duration and age

Variables	Age group (yr)	Group A (famotidine)					Group B (control)
		1-10 d	11-20 d	21-30 d	> 31 d	Total	1-10 d	11-20 d	21-30 d	> 31 d	Total
Duration of hospital stay (recovered cases), group A (n = 78), group B (n = 73)	11-20	0	2	0	0	2	0	0	0	0	0
	21-30	0	1	1	0	2	0	0	0	0	0
	31-40	3	4	1	0	8	8	8	0	0	16
	41-50	4	5	0	0	9	0	8	0	0	8
	51-60	13	8	3	0	24	4	8	4	0	16
	61-70	5	13	1	0	19	0	16	4	0	20
	71-80	5	4	1	0	10	1	4	4	0	9
	> 81	1	2	1	0	4	0	4	0	0	4
Total (%)		31 (40)	39 (50)	8 (10)	0 (0)	78 (100)	13 (18)	48 (66)	12 (16)	0 (0)	73 (100)
Duration of ICU stay (recovered cases), group A (n = 78), group B (n = 73)	11-20	2	0	0	0	2	0	0	0	0	0
	21-30	1	1	0	0	2	0	0	0	0	0
	31-40	6	2	0	0	8	12	4	0	0	16
	41-50	5	4	0	0	9	8	0	0	0	8
	51-60	20	4	0	0	24	12	0	4	0	16
	61-70	8	11	0	0	19	8	12	0	0	20
	71-80	6	3	1	0	10	1	4	4	0	9
	> 81	1	2	1	0	4	0	4	0	0	4
Total (%)		49 (63)	27 (34.5)	2 (2.5)	0 (0)	78 (100)	41 (56)	24 (33)	8 (11)	0 (0)	73 (100)
Duration of hospital/ICU stay (death cases), group A (n = 26), group B (n = 32)	11-20	0	0	0	0	0	0	0	0	0	0
	21-30	0	0	0	0	0	4	0	0	0	4
	31-40	0	1	0	0	1	0	0	0	0	0
	41-50	0	7	0	0	7	12	0	0	0	12
	51-60	1	8	1	0	10	0	0	0	0	0
	61-70	0	4	2	0	6	0	1	1	2	4
	71-80	0	2	0	0	2	11	0	0	0	11
	> 81	0	0	0	0	0	0	0	0	0	0
Total (%)		1 (4)	22 (84.5)	3 (11.5)	0 (0)	26 (100)	27 (88)	1 (3)	1 (3)	2 (6)	31 (100)
Time to clinical improvement (recovered cases), group A (n = 78), group B (n = 73)	11-20	2	0	0	0	2	0	0	0	0	0
	21-30	1	1	0	0	2	0	0	0	0	0
	31-40	6	2	0	0	8	3	10	3	0	16
	41-50	5	3	1	0	9	2	3	3	0	8
	51-60	17	6	1	0	24	7	9	0	0	16
	61-70	10	8	1	0	19	6	11	3	0	20
	71-80	5	4	1	0	10	2	6	1	0	9
	> 81	4	0	0	0	4	1	2	1	0	4
Total (%)		50 (64)	24 (31)	4 (5)	0 (0)	78 (100)	21 (29)	41 (56)	11 (15)	0 (0)	73 (100)
Time to negative PCR (recovered cases), group A (n = 78), group B (n = 73)	11-20	0	2	0	0	2	0	0	0	0	0
	21-30	0	0	2	0	2	0	0	0	0	0
	31-40	0	7	1	0	8	0	9	7	0	16
	41-50	0	7	1	1	9	0	4	4	0	8
	51-60	0	12	11	1	24	0	8	5	3	16
	61-70	0	6	12	1	19	0	4	11	5	20
	71-80	0	4	5	1	10	0	1	4	4	9
	> 81	0	3	0	1	4	0	0	4	0	4
Total (%)		0 (0)	41 (53)	32 (41)	5 (6)	78 (100)	0 (0)	26 (36)	35 (48)	12 (16)	73 (100)
Time to symptomatic improvement (recovered cases), group A (n = 78), group B (n = 73)	11-20	0	2	0	0	2	0	0	0	0	0
	21-30	0	2	0	0	2	0	0	0	0	0
	31-40	2	6	0	0	8	2	13	1	0	16
	41-50	4	4	1	0	9	0	6	2	0	8
	51-60	11	12	1	0	24	1	11	3	1	16
	61-70	7	11	1	0	19	0	11	8	1	20
	71-80	3	7	0	0	10	0	3	2	4	9
	> 81	1	3	0	0	4	0	1	3	0	4
Total (%)		28 (36)	47 (60)	3 (4)	0 (0)	78 (100)	3 (4)	45 (62)	19 (26)	6 (82)	73 (100)

ICU: Intensive care unit; PCR: Polymerase chain reaction.